Thus, while low‐dose DNMTi and HDACi cooperate with the absence of myeloid NF‐κB p50 to slow HR neuroblastoma tumor growth, we did not identify any alterations in the number or phenotype of tumor T cells or myeloid cells to account for the benefit of azacytidine and ITF‐2357 in this setting. The gene discussed is NFKB1; the disease is neoplasm.